Eli Lilly's Foundayo Gains Traction in Obesity Drug Market

Eli Lilly’s oral GLP-1 obesity medication, Foundayo, saw its share price rise more than 2% after Citi analysts released a survey indicating strong physician support. The data suggests the drug could narrow the market-share gap with Novo Nordisk’s injectable Wegovy pill, which currently leads.

CNBC

GLP-1 agonists dominate obesity treatment, with injectables like Wegovy leading early adoption. Oral options aim to broaden access, especially for patients deterred by injections or fasting requirements. Foundayo’s lack of food or water restrictions contrasts with Wegovy’s fasting protocol, a factor increasingly cited by prescribers.

CNBC

• Eli Lilly – developer of Foundayo

CNBC

• Novo Nordisk – maker of Wegovy

CNBC

• Citi analysts – conducted physician survey and provided forecasts

CNBC

• Endocrinologists – primary prescribers

CNBC

• 74% of surveyed endocrinologists reported that Wegovy’s fasting requirements influence prescribing choices.

CNBC

• Approximately 80% of Foundayo prescriptions are for patients who had not previously used a GLP-1 therapy.

CNBC

• Citi projects Foundayo sales of $2.8 billion in 2026, versus a consensus estimate of $1.5 billion.

CNBC

Citi analysts note physicians are willing to trade modest efficacy for ease of use, highlighting the oral pill’s no-fasting advantage. Lilly’s earnings call confirmed most new prescriptions come from patients newly entering the GLP-1 class, expanding the market. Novo Nordisk has not responded.

CNBC

Some clinicians cite Wegovy’s slightly higher weight-loss efficacy, arguing convenience may not fully offset the performance gap. Wegovy’s early oral launch also shows brand recognition and first-mover advantage remain hurdles for Foundayo.

CNBC

Sales forecasts diverge sharply: Citi’s $2.8 billion projection contrasts with the broader market consensus of $1.5 billion for 2026. The sources also lack comparative clinical efficacy data, leaving the magnitude of the “efficacy trade-off” unclear.

CNBC

If Foundayo reaches the projected $2.8 billion sales, oral GLP-1 therapies would capture a larger share of the obesity market, potentially reshaping prescribing patterns and expanding the overall GLP-1 patient base.

CNBC

• “That's why we were pleased to see in the Citi survey that 74% of endocrinologists say Wegovy's fasting requirements are having a some impact on their prescribing decision.” — Citi survey

CNBC

• “This is all positive for category growth, but was mostly understood by us, as we heard on Lilly's late April earnings call that about 80% of the prescriptions for its oral Foundayo are for people who previously weren't taking a GLP-1.” — Eli Lilly, late April earnings call

CNBC

• “But Lilly's pill has a key advantage over Wegovy in that it does not have any food or water restrictions.” — Citi analysts

CNBC

Citi’s forecast positions Foundayo for a strong 2026 revenue run-rate, but analysts will watch upcoming quarterly results for evidence of sustained prescription growth and any competitive response from Novo Nordisk.

CNBC